BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $380,869 | +2.2% | 53,795 | +1.6% | 0.00% | 0.0% |
| Q2 2023 | $372,641 | -17.3% | 52,932 | -2.0% | 0.00% | -25.0% |
| Q1 2023 | $450,502 | -25.2% | 54,017 | +3.0% | 0.00% | -33.3% |
| Q4 2022 | $602,344 | -5.3% | 52,469 | +4.0% | 0.01% | -14.3% |
| Q3 2022 | $636,000 | +20.2% | 50,443 | +0.8% | 0.01% | +40.0% |
| Q2 2022 | $529,000 | -33.1% | 50,043 | +2.9% | 0.01% | -16.7% |
| Q1 2022 | $791,000 | +18.6% | 48,640 | +1.0% | 0.01% | +20.0% |
| Q4 2021 | $667,000 | -4.2% | 48,142 | -0.5% | 0.01% | -16.7% |
| Q3 2021 | $696,000 | -8.4% | 48,403 | +0.7% | 0.01% | 0.0% |
| Q2 2021 | $760,000 | +45.3% | 48,082 | -6.5% | 0.01% | +20.0% |
| Q1 2021 | $523,000 | +37.3% | 51,399 | +0.4% | 0.01% | +66.7% |
| Q4 2020 | $381,000 | +112.8% | 51,204 | -1.9% | 0.00% | +50.0% |
| Q3 2020 | $179,000 | +7.8% | 52,220 | +50.2% | 0.00% | 0.0% |
| Q2 2020 | $166,000 | +130.6% | 34,772 | -3.9% | 0.00% | +100.0% |
| Q1 2020 | $72,000 | – | 36,168 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management, LLC | 1,744,356 | $18,455,000 | 9.59% |
| RA Capital Management | 4,347,456 | $45,996,000 | 3.30% |
| Cormorant Asset Management, LP | 1,168,000 | $12,357,000 | 2.84% |
| Baker Brothers Advisors | 5,867,031 | $62,073,000 | 0.79% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 907,920 | $9,606,000 | 0.39% |
| QVT Financial LP | 525,734 | $5,562,000 | 0.32% |
| EAM Investors, LLC | 114,548 | $1,212,000 | 0.22% |
| FRANKLIN STREET ADVISORS INC /NC | 93,000 | $984,000 | 0.20% |
| THB ASSET MANAGEMENT | 301,529 | $3,190,000 | 0.19% |
| TPG Group Holdings (SBS) Advisors, Inc. | 1,162,269 | $12,297,000 | 0.13% |